Medicines Co
MDCO
MDCO was delisted on the 3rd of January, 2020.
181 hedge funds and large institutions have $2.62B invested in Medicines Co in 2016 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 81 increasing their positions, 59 reducing their positions, and 27 closing their positions.
306% more call options, than puts
Call options by funds: $79.2M | Put options by funds: $19.5M
37% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 59
5% less funds holding
Funds holding: 190 → 181 (-9)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
16% less capital invested
Capital invested by funds: $3.14B → $2.62B (-$517M)
30% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$15.1M |
| 2 |
JP Morgan Chase
New York
|
+$13.6M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$9.8M |
| 4 |
PA
Pinnacle Associates
New York
|
+$9.61M |
| 5 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$8.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
Antipodean Advisors
New York
|
-$33.4M |
| 2 |
PC
PointState Capital
New York
|
-$23.6M |
| 3 |
SPC
Slate Path Capital
New York
|
-$21.3M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$14.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SEC
201
Seven Eight Capital
New York
| – | -$78K | -2,100 | Closed |
|
|
QT
202
Quantbot Technologies
New York
| – | -$60K | -1,630 | Closed |
|
|
EWM
203
Evercore Wealth Management
New York
| – | -$31K | -828 | Closed |
|
|
MAM
204
Meeder Asset Management
Dublin,
Ohio
| – | -$14K | -381 | Closed |
|
205
Fifth Third Bancorp
Cincinnati,
Ohio
| – | -$7K | -194 | Closed |
|
|
TRCT
206
Tower Research Capital (TRC)
New York
| – | -$3K | -82 | Closed |
|
|
IA
207
IFP Advisors
Tampa,
Florida
| – | -$1K | -24 | Closed |
|
MDCO Hedge Fund Activity: Q1 2016 in Review
181 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q1 2016, worth a combined $2.62B — down 16% from $3.14B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of MDCO and 19 opened new positions — a net loss of 8 holders — while 59 trimmed existing stakes and 81 added.
The largest buyer was Citadel Advisors, adding an estimated $15.1M. The largest seller was Antipodean Advisors, cutting an estimated $33.4M.
- 181 institutional investors held Medicines Co (MDCO) as of Q1 2016, down from 190 in Q4 2015.
- Funds reported $2.62B of Medicines Co stock for Q1 2016, down 16% quarter-over-quarter.
- 19 funds opened new Medicines Co positions in Q1 2016 and 27 closed out, a net change of -8 holders.
- The largest Medicines Co buyer in Q1 2016 was Citadel Advisors, an estimated $15.1M added.
- The largest Medicines Co seller in Q1 2016 was Antipodean Advisors, an estimated $33.4M sold.
Based on aggregated 13F filings for Q1 2016.